Mcl-1 inhibition overcomes intrinsic and acquired Regorafenib resistance in Colorectal Cancer
Xiangping Song, Lin Shen, Jingshan Tong, Chaoyuan Kuang, Shan Zeng, Robert E. Schoen, Jian Yu, Haiping Pei, Lin Zhang
Abstract
, which block degradation of the pro-survival Bcl-2 family protein Mcl-1. We tested if Mcl-1 inhibition can be used to develop a precision combination therapy for overcoming regorafenib resistance. METHODS: -mutant and -WT patient-derived organoid (PDO) and xenograft (PDX) tumor models. RESULTS: -WT CRCs. CONCLUSIONS: mutations might be a potential biomarker predicting for response to the regorafenib/Mcl-1 inhibitor combination.
Topics & Concepts
RegorafenibColorectal cancerCancer researchMutantChemistryCancerMedicineBiologyPharmacologyInternal medicineBiochemistryGeneMicrotubule and mitosis dynamicsCancer-related Molecular PathwaysCancer Mechanisms and Therapy